Interazioni tra farmaci
Nivolumab + Ponesimod
Gravità: Moderata
Nivolumab and Ponesimod: moderate interaction.
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
Sintesi
Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
Cosa significa questa interazione in parole semplici
Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
Perché avviene
Ponesimod sequesters lymphocytes in lymphoid tissue via S1P receptor modulation, which may counteract the T-cell activation sought with PD-1 blockade.
Cosa fare
Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
Cosa chiedere al farmacista
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per sbloccare le indicazioni complete sulla gestione di Nivolumab e Ponesimod, le note aggiuntive, il dettaglio delle evidenze e il controllo delle interazioni per un'intera prescrizione.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Provi Pro+ gratis per 7 giorni sul web. Nessuna carta.
Altre interazioni di Nivolumab
- Nivolumab + Thalidomide Maggiore
- Dexamethasone-tobramycin + Nivolumab Moderata
- Dexamethasone + Nivolumab Moderata
- Efgartigimod / hyaluronidase sc + Nivolumab Moderata
- Efgartigimod alfa + Nivolumab Moderata
- Nivolumab + Rozanolixizumab Moderata
Altre interazioni di Ponesimod
- Fingolimod + Ponesimod Controindicata
- Ponesimod + Siponimod Controindicata
- Amiodarone + Ponesimod Maggiore
- Amisulpride + Ponesimod Maggiore
- Anagrelide + Ponesimod Maggiore
- Anti-thymocyte + Ponesimod Maggiore
Domande frequenti
Can I take Nivolumab with Ponesimod?
MediHelp rates the interaction as moderate. Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
How serious is the interaction between Nivolumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
